Evidence map›Paper›PMID 40001321›Full record

ArticleThe journal of pathology. Clinical research2025

Comprehensive transcriptomic profiling reveals molecular characteristics and biomarkers associated with risk stratification in papillary thyroid carcinoma.

Congcong Yan, Chen Zheng, Jiaxing Luo, Xue Wu, Xinyu Meng, Chaoyue Lv, Shurong Shen, Meng Zhou, Ouchen Wang

Abstract read
In one paragraph

Article in The journal of pathology. Clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Preoperative Co-Mutation of BRAFCancer medicine · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Congcong Yan *School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, PR China.
Chen Zheng *Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, PR China.
Jiaxing LuoDepartment of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, PR China.
Xue WuDepartment of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, PR China.
Xinyu MengDepartment of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, PR China.
Chaoyue LvDepartment of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, PR China.
Shurong ShenDepartment of Surgical Oncology, Wenzhou Central Hospital and Sixth People's Hospital of Wenzhou, Wenzhou, PR China.
Meng ZhouSchool of Biomedical Engineering, Wenzhou Medical University, Wenzhou, PR China.ORCID 0000-0001-9987-9024
Ouchen WangDepartment of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, PR China.

Funding

Major Science and Technology Innovation Program of Wenzhou ZY2021008Major Science and Technology Innovation Program of Wenzhou ZY2022008
6 · The paper itself

Abstract

Papillary thyroid carcinoma (PTC) is one of the most common endocrine malignancies, with varying levels of risk and clinical behavior. A better understanding of the molecular characteristics could improve molecular diagnosis and risk assessment. In this study, we performed whole transcriptomic sequencing on 113 PTC cases, including 70 high-risk and 43 low-risk Chinese patients. Comparative transcriptional profiling analysis revealed two functionally distinct patterns of gene dysregulation between the risk subtypes. Low-risk PTCs showed significant upregulation of immune-related genes and increased immune cell infiltration, whereas high-risk PTCs presented extensive alterations in gene expression and activation of oncogenic signaling pathways. Additionally, we developed a 31-gene transcriptomic signature (PTCrisk) for differentiating high-risk from low-risk PTCs, which was validated across both in-house and external multicenter cohorts. PTCrisk scores were positively correlated with key clinicopathological features, including tumor size, lymph node metastasis, TNM stage, and BRAF mutation status. Overall, our study provides further molecular insights into PTC risk stratification and may contribute to the development of personalized therapeutic strategies for PTC patients.

Indexed as

Biomarkers, TumorGene Expression ProfilingThyroid Cancer, PapillaryThyroid NeoplasmsTranscriptomeAdultAgedFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMutationProto-Oncogene Proteins B-rafRisk AssessmentRisk FactorsBiomarkers, TumorBRAF protein, humanProto-Oncogene Proteins B-rafbiomarkerpapillary thyroid carcinomarisk stratificationtranscriptomics

Identifiers

PMID40001321
PMCPMC11860273

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.